|
Pathogen (Target Population)
|
Type of Vaccine
|
Probability of Successful Development
|
Cost of Development (dollars)
|
Minimum Time to Steady State of Vaccine Use
|
|
Dengue virus
(Infants and children in endemic areas; travelers to endemic areas)
|
Attenuated live vector virus containing gene for broadly cross-reacting protective antigen
|
0.75
|
25,000,000
|
12
|
|
Escherichia coli
(enterotoxigenic)
(Infants < 6 months)
|
A combination of purified colonization factor antigens and possibly other antigens
|
0.50
|
25,000,000
|
12
|
|
Genetically engineered attenuated strains
|
0.70
|
37,500,000
|
12
|
|
Hemophilus influenzae type b
(Infants)
|
Conjugated polysaccharide
|
0.90
|
15,000,000
|
8
|
|
Hepatitis A virus
(Susceptibles of all ages; routine for preschool children)
|
Attenuated live virus
|
0.95
|
15,000,000
|
9
|
|
Polypeptide recombinant vaccine produced in yeast
|
0.95
|
25,000,000
|
10
|
|
Hepatitis B virus
(Areas with high perinatal infection: all infants at birth (if possible). Other areas: all infants, simultaneous with other vaccinations)
|
Polypeptide produced by recombinant DNA technology
|
0.99
|
5,000,000
|
3
|
|
Japanese encephalitis virus
(Children in epidemic and endemic areas; foreign visitors to epidemic regions)
|
Inactivated virus produced in cell culture
|
0.50
|
50,000,000
|
9.5
|
|
Mycobacterium leprae
(Immunoprophylactic: all children in endemic areas. Immunotherapeutic: all recently infected individuals)
|
Armadillo-derived M. leprae
|
0.50
|
25,000,000
|
15
|
|
Neisseria meningitidis
(Infants, 3 to 6 months)
|
Conjugated capsular polysaccharides. Groups A,C,Y, and W135
|
0.50
|
30,000,000
|
10
|
|
Parainfluenza viruses
(Infants)
|
Trivalent, subunit vaccine (which must contain fusion proteins)
|
0.80
|
25,000,000
|
10
|
|
Plasmodium spp.
(All infants at risk, military personnel, travelers)
|
Plasmodium falciparum, synthetic or recombinant sporozoite antigen preparation
|
0.50
|
25,000,000
|
8.5
|
|
Multivalent synthetic or recombinant sporozoite antigen preparation (P. falciparum, P. vivax, P. ovale, P. malariae)
|
0.50
|
35,000,000
|
11
|
